GO
Loading...

Eli Lilly and Co

More

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • Jan 20- Johnson& Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck& Co.. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many...

  • Early movers: BAC, BBY, GOOG, APPL & more Thursday, 15 Jan 2015 | 8:28 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • *AstraZeneca sees $3.5 bln sales, analysts' numbers lower. *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

  • Martha Stewart ordeal changed me: Sam Waksal Tuesday, 13 Jan 2015 | 11:24 AM ET
    Sam Waksal of Kadmon Pharmaceuticals

    "Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Your first trade for Monday Friday, 9 Jan 2015 | 5:56 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Early movers: COST, FDO, GOOG, HLF, GM & more Thursday, 8 Jan 2015 | 8:08 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 earnings and revenue just shy of Wall Street expectations. Lilly, which is betting on its rejuvenated pipeline of drugs, particularly for diabetes, oncology and animal health, forecast adjusted 2015 earnings of $3.10 to $3.20 per share.

  • Early movers: JCP, AXP, PEP, SNE, SIRI & more Wednesday, 7 Jan 2015 | 7:55 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 revenue shy of Wall Street expectations. The drugmaker expects sales of $20.3 billion to $20.8 billion for the year, it said on Wednesday. The company, which is betting on its rejuvenated pipeline of drugs particularly for diabetes, oncology and...

  • HALFTIME FINAL TRADES 1/6/15 Tuesday, 6 Jan 2015 | 2:35 PM ET
  • Early movers: CVEO, YHOO, NVS, GM, CLF & more Friday, 2 Jan 2015 | 7:45 AM ET
    NYSE exchange floor

    Some of the names on the move ahead of the open.

  • Lawyers cash in on favors from state prosecutors Friday, 19 Dec 2014 | 10:54 AM ET
    Gary King speaks during the Democratic Party for New Mexico 2014 Governor Forum in Albuquerque, N.M., May, 2014.

    The partnership is part of an industry pairing plaintiffs' lawyers with state attorneys general to sue companies. The NYT reports.

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Mario Draghi is all over the place on ECB action Thursday, 4 Dec 2014 | 10:28 AM ET
    European Central Bank Governor Mario Draghi speaks at a news conference during the World Bank/IMF annual meetings in Washington, Oct. 11, 2014.

    European stocks weakened and the euro shot higher as the ECB chief implied any initiative to purchase sovereign debt isn't imminent.

  • Midday movers: Biogen Idec, Priceline, BP & more Tuesday, 2 Dec 2014 | 12:43 PM ET

    Some of Tuesday's midday movers